Influenza Vaccines for the World

2-4 April 2019, Royal College of Physicians of Edinburgh, Edinburgh, Scotland, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Tuesday 2nd April 2019

SESSION 1:
OPENING PLENARY SESSION

Moderator: John Oxford (Blizzard Institute, Queen Mary College London / hVIVO Ltd / Oxford Media & Medicine, London, UK)

OPENING KEYNOTE:
‘Replication and pathogenesis of influenza viruses’

Paul Digard (The Roslin Institute, University of Edinburgh, Midlothian, Scotland, UK)

SESSION 2:
INFLUENZA VACCINES & PUBLIC HEALTH CHALLENGES

Moderator: John Oxford (Blizzard Institute, Queen Mary College London / hVIVO Ltd / Oxford Media & Medicine, London, UK)

KEYNOTE:
‘WHO strategy for influenza 2019-2030: The “priorities” and most urgent needs to improve seasonal influenza control and pandemic preparedness’

Ann Moen (WHO, Geneva, Switzerland)

KEYNOTE:
‘Influenza vaccines: From science into public health policy’

Jon Van Tam (UK Department of Health, London, UK)

‘Influenza: Why vaccine uptake matters’
Bram Palache (IFPMA/FluPal Consultancy BV, Amstelveen, The Netherlands)

Coffee Break & Poster Set-Up

SESSION 3:
PANDEMIC VACCINES & PREPAREDNESS

Moderator: Jon Van Tam (UK Department of Health, London, UK)

KEYNOTE:
‘The military Final Push: An international attempt to stop a pandemic at source by vaccination’

John Oxford (Blizzard Institute, Queen Mary College London / hVIVO Ltd / Oxford Media & Medicine, London, UK)

‘Pandemics, vaccine availability and use’
Lone Simonsen (The George Washington University, Washington DC, USA)

‘Influenza Pandemics: Are we ready for the next one?’
Bram Palache (IFPMA/FluPal Consultancy BV, Amstelveen, The Netherlands)

Lunch Break & Posters

SESSION 4:
INFLUENZA VACCINES DEVELOPMENTS – I

Moderator: To be confirmed

KEYNOTE:
‘The young and the old as a challenge for influenza vaccine development’

Timo Vesikari (University of Tampere, Tampere, Finland)

KEYNOTE:
‘Egg-based vs. cell culture-based human influenza vaccines’

John McCauley (Francis Crick Institute, London, UK)

‘Getting closer to the market: M-001 universal flu vaccine pivotal phase 3 trial’
Tamar Ben-Yedidia (BiondVax Pharmaceuticals Ltd., Ness Ziona, Israel)

Tea Break & Posters

SESSION 5:
INFLUENZA VACCINES DEVELOPMENTS – II
ANTIGEN DESIGN & CHARACTERIZATION

Moderator: To be confirmed

KEYNOTE:
‘Recent progress in novel, cross-reactive and universal influenza vaccines’

Sean Tucker (VAXART Inc, South San Francisco, California, USA)

‘Next-generation broadly reactive influenza vaccines’
James D. Allen (University of Georgia, Athens, Georgia, USA)

‘Development of a T cell-based universal influenza vaccine’
Chris Ellis (Vaccitech Ltd., Oxford, UK)

‘Immune engineering: A strategy to couple B cell and T cell immunity for improved pandemic and universal influenza vaccines’
Lenny Moise (EpiVax Inc., Providence, Rhode Island, USA)

 

IVW 2019 Delegates

Login details will be supplied after you have registered for the event.


IVW 2019 Sponsors

  • APACI
  • Vaxxas
  • Sanofi Pasteur
  • Inovio Pharmaceuticals
  • NanoPass
  • Novavax
  • Vismederi
  • FluConsult
  • SPbSRIVS
  • InDevR
  • isirv
  • Janssen
  • Vaxart
  • hVIVO
  • MedImmune
  • Medicago
  • Eurocine Vaccines

IVW 2019 Downloads

IVW 2019 Leaflet

IVW 2019 Mailing List

Name
E-mail Address
What is 3+2-1?